Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. develops fully human anti-thymocyte immunoglobulin and multi-specific human immunoglobulin G therapies for type 1 diabetes and other autoimmune diseases. Its lead program, SAB-142, is a disease-focused immunotherapy candidate for autoimmune type 1 diabetes, supported by the company’s transchromosomic cattle, or Tc-Bovine, production system for generating targeted hIgG antibodies.
Recurring news themes include SAB-142 clinical and mechanistic data, scientific conference presentations, financial results and business updates, and capital actions such as common stock and pre-funded warrant offerings that fund clinical development, manufacturing, regulatory activity and general corporate purposes.
SAB Biotherapeutics (Nasdaq: SABS) commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants on March 17, 2026. The company also plans to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities.
Proceeds, together with existing cash and marketable securities, are intended primarily to fund continued development of SAB-142 (clinical trials, manufacturing, regulatory), and for working capital and general corporate purposes. The offering is made on a Form S-3 shelf registration declared effective January 7, 2026, and is subject to market conditions.
SAB BIO (Nasdaq: SABS) reported additional Phase 1 data for SAB-142 in adults with established type 1 diabetes showing early signals of C‑peptide preservation at Day 120 in treated participants versus placebo. The small cohort (n=6; 4 treated, 2 placebo) showed biomarker evidence of T‑cell exhaustion. SAB‑142 has advanced to the registrational Phase 2b SAFEGUARD trial with topline data expected 2H 2027.
SAB BIO (Nasdaq: SABS) reported full‑year 2025 results and business highlights. Key developments include dosing multiple patients in the registrational Phase 2b SAFEGUARD study with enrollment on track to complete by end‑2026 and topline data expected in 2H 2027.
Other milestones: positive Phase 1 data supporting safety and redosability of SAB‑142, a $175 million oversubscribed private placement (with strategic investor Sanofi), and a cash position of $143.5 million providing runway through 2028.
SAB Biotherapeutics (Nasdaq: SABS) said members of management will participate in two investor conferences in Miami Beach in March 2026: the Leerink Partners Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11 at 8:30 a.m. ET.
Both appearances are in a fireside chat format. According to the company, live webcasts and archived recordings will be available in the Investors & Media section of the company website at www.sab.bio.
SAB Biotherapeutics (Nasdaq: SABS) announced that management will participate in two investor conferences in February 2026: Guggenheim Securities Emerging Outlook: Biotech Summit on February 11, 2026 (10:30 a.m. ET, New York) and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 (8:40 a.m. ET, virtual).
According to the company, both appearances include fireside chats and will be available live and on demand via the Investors & Media section of the company website at www.sab.bio.
SAB BIO (Nasdaq: SABS) announced two board appointments effective January 7, 2026: David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director.
Management highlights Zaccardelli's 20+ years of biopharma leadership and his role in the successful launch of Ohtuvayre, and describes Jain's two decades of experience in autoimmune and inflammatory disease drug development. Both appointees are presented as bringing complementary expertise to support clinical execution and advancement of SAB-142, the company's fully human anti-thymocyte immunoglobulin candidate for type 1 diabetes and other autoimmune diseases.
SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.
A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.
SAB BIO (Nasdaq: SABS) announced the first patient was dosed with SAB-142 in the Phase 2b registrational SAFEGUARD trial on Dec 18, 2025. The trial targets stage 3 type 1 diabetes using a fully human anti-thymocyte immunoglobulin intended as a disease-modifying therapy. Enrollment is ongoing at multiple global sites, including the U.S., Australia, and New Zealand, with European sites joining soon. The company plans to share Phase 2b data in 2H 2027.
SAB BIO (Nasdaq: SABS) announced positive confirmatory Phase 1 results for SAB-142, an hATG candidate for stage 3 type 1 diabetes (T1D). In 68 treated participants (healthy volunteers and T1D patients), SAB-142 showed 0% serum sickness (0/68), 0% anti-drug antibody events (0/68), no drug-related serious adverse events, and transient lymphopenia that resolved to baseline within 1–3 days in 100% of subjects (68/68). Most adverse events were mild and infusion-related. A registrational Phase 2b SAFEGUARD trial is underway and recruiting globally, with the company on track to dose the first patient by year-end.
SAB BIO (Nasdaq: SABS) will present clinical data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), December 9-11, 2025 in Singapore. Presentations on December 10, 2025 highlight Phase 1 results reporting a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile without serum sickness or anti-drug antibodies at the target dose.
The company said it is currently in Phase 2b development for delaying progression of new-onset Stage 3 type 1 diabetes and expects to report additional Phase 1 data and dose the first Phase 2b SAFEGUARD patient later in 2025. Presentations will be posted on the company website.